secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0000950170-21-003064
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector reports Q3 net income $126.6M ($1.56/share) vs loss year-ago; GSK collaboration boosts revenue
--------------------------------------------------------------------------------

- Collaboration revenue $182.4M (vs $5.9M YoY) driven by $500M upfront from GSK deal.
- Cash, cash equivalents & marketable securities $777.9M as of Sep 30, 2021.
- Initiated Phase 2 trial of AL001 in ALS patients with C9orf72 mutation; primary endpoint safety & PK/PD.
- Sam Jackson, M.D., appointed interim CMO; Linda Rubinstein interim CFO; Elizabeth Garofalo, M.D. joins board.
- Net income $126.6M ($1.56 diluted EPS) compared to net loss $52.7M ($0.67 loss) in Q3 2020.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017021003064/0000950170-21-003064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017021003064/alec-20211104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-003064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer